Table 3 Baseline demographic and clinical characteristics in high and low SMI group
variable | Low SMI (n = 23) | high SMI (n = 39) | P value |
|---|---|---|---|
Sex (male) | 18(78.3) | 31 (79.5) | 1.000 |
Age (year) | 61.0 ± 11.6 | 57.9 ± 9.8 | 0.159 |
BMI (kg/m2) | |||
 Male | 21.7 ± 2.2 | 25.5 ± 3.2 |  < 0.001 |
 Female | 23.0 ± 3.2 | 22.2 ± 3.3 | 0.686 |
SMI (kg2/m2) | |||
 Male | 38.2 ± 3.3 | 48.8 ± 5.2 |  < 0.001 |
 Female | 33.9 ± 2.7 | 42.1 ± 4.2 | 0.003 |
SML (%) | |||
 Male | − 0.4 ± 3.0 | − 2.1 ± 3.1 | 0.071 |
 Female | − 2.3 ± 2.9 | − 1.0 ± 3.4 | 0.661 |
Aetiology (HBV/HCV/others) | 13 (56.5)/3 (13.0)/7 (30.4) | 36 (92.3)/0/3 (7.7) | 0.001 |
BCLC (0/A/B) | 1 (4.3)/20 (87.0)/2 (8.7) | 5 (12.8)/33 (84.6)/1(2.6) | 0.329 |
Tumor number (solitary/multiple) | 19 (82.6)/4 (17.4) | 35 (89.7)/4(10.3) | 0.454 |
Maximum tumor diameter (cm) | 4.8 ± 2.5 | 4.0 ± 1.8 | 0.115 |
Differentiation(well or moderate/poor) | 21 (91.3)/2 (8.7) | 33 (84.6)/6 (15.4) | 0.698 |
Hepatectomy (major/minor) | 20 (87.0)/3 (13.0) | 29 (74.4)/10 (25.6) | 0.338 |
MVI (presence/absence) | 5 (21.7)/18 (78.3) | 8 (20.5)/31 (79.5) | 1.000 |
Cirrhosis (presence/absence) | 8 (34.8)/15 (65.2) | 28 (71.8)/11 (28.2) | 0.007 |
TACE sessions (1/2/3) | 3 (13.0)/4 (17.4)/16 (69.6) | 2 (5.1)/8 (20.5)/29 (74.4) | 0.615 |
Child–Pugh class (A/B) | 23 (100.0)/0 | 39 (100.0)/0 | - |
MELD-Na score | 7.0 (6.0 ~ 9.0) | 7.0 (6.0 ~ 9.0) | 0.372 |
ALB (g/L) | 38.8 ± 3.3 | 40.2 ± 4.0 | 0.168 |
TBIL (umol/L) | 14.4 (11.7 ~ 18.5) | 15.9 (11.9 ~ 22.6) | 0.590 |
ALT (U/L) | 21.0 (16.0 ~ 31.0) | 25.0 (18.0 ~ 37.0) | 0.166 |
AST (U/L) | 27.2 (20.2 ~ 36.1) | 30.2 (23.2 ~ 37.0) | 0.175 |
PLT (109/L) | 170.2 ± 66.7 | 153.1 ± 54.6 | 0.278 |
AFP (ng/ml) | 20.2 (2.9 ~ 414.9) | 21.3 (2.6 ~ 152.3) | 0.498 |
NLR | 1.9 ± 0.9 | 2.0 ± 1.0 | 0.710 |